Home / Market News / $AQST

$AQST news and market catalysts

The 11 most recent market catalysts affecting $AQST, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

11 catalysts 4 high impact 4 bullish 3 bearish Pharmaceuticals
Nov 3, 2026 Corporate Catalyst Bearish Impact 85
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results
Aquestive Therapeutics reported a substantial 40% year-over-year decline in Q3 2026 revenues, primarily due to fluctuations in Suboxone product orders, and a wider non-GAAP adjuste…
Oct 27, 2026 Corporate Catalyst Neutral Impact 55
Aquestive Therapeutics to Report Third Quarter 2026 Financial Results on November 3
Aquestive Therapeutics has scheduled its Q3 2026 financial results release for November 3, 2026, after market close, followed by a conference call on November 4. This is a standard…
Oct 15, 2026 Corporate Catalyst Neutral Impact 85
FDA Accepts Aquestive Therapeutics’ Anaphylm NDA Resubmission; PDUFA Goal Action Date Set For March 16, 2027
Aquestive Therapeutics announced that the FDA has accepted its resubmission of the New Drug Application (NDA) for Anaphylm, classifying it as a Class 2 response and setting a PDUFA…
Sep 17, 2026 Corporate Catalyst Bullish Impact 75
Aquestive Therapeutics Resubmits FDA Application for Pocket-Sized Allergy Treatment
Aquestive Therapeutics has officially resubmitted its New Drug Application for Anaphylm to the FDA, addressing the issues raised in a previous Complete Response Letter (CRL). This …
Sep 17, 2026 Corporate Catalyst Neutral Impact 85
Aquestive Therapeutics Announces Resubmission Of NDA To FDA For Anaphylm Sublingual Film For Type I Allergic Reactions
This headline is a significant corporate catalyst for Aquestive Therapeutics (AQST). The resubmission of the NDA for Anaphylm indicates that the company has addressed previous FDA …
Aug 24, 2026 Corporate Catalyst Neutral Impact 55
HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target
This filing indicates that HC Wainwright & Co. analyst Raghuram Selvaraju has reaffirmed his 'Buy' rating and $10 price target for Aquestive Therapeutics (AQST). This is a continua…
Aug 11, 2026 Corporate Catalyst Bullish Impact 75
Aquestive Therapeutics Q2 EPS $(0.18) Misses $(0.12) Estimate, Sales $13.819M Beat $11.418M Estimate
This headline presents a classic mixed bag for Aquestive Therapeutics (AQST). The substantial revenue beat indicates strong underlying demand for their products, which is a positiv…
Aug 11, 2026 Corporate Catalyst Bearish Impact 55
Aquestive Therapeutics Affirms FY2026 Sales Guidance of $46.000M-$50.000M vs $50.584M Est
Aquestive Therapeutics (AQST) has affirmed its FY2026 sales guidance, keeping it within the previously stated range of $46.000 million to $50.000 million. This is a routine update,…
Aug 10, 2026 Corporate Catalyst Bullish Impact 75
Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study
Aquestive Therapeutics (AQST) has reported successful human factors and pharmacokinetic studies for Anaphylm, their severe allergy treatment. These studies directly address the iss…
Aug 10, 2026 Corporate Catalyst Bullish Impact 85
Aquestive Therapeutics shares are trading higher after the company announced results from its human factors validation study and pharmacokinetic study for Anaphylm sublingual film
The positive human factors validation and pharmacokinetic study results for Anaphylm are a significant corporate catalyst for Aquestive Therapeutics. This data suggests the subling…
Aug 10, 2026 Corporate Catalyst Bearish Impact 75
Aquestive Says Anaphylm Human Factors Study Cut Median Pouch-Opening Time To 3 Seconds From 17, With NDA Resubmission On Track For Q3 2026
This headline is a significant positive catalyst for Aquestive (AQST). The dramatic reduction in pouch-opening time for Anaphylm addresses a key concern for a life-saving medicatio…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.